The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
Commercial Bank of Dubai PSC
CBD.AE · DFM · AED · Market cap $29.3B
Commercial Bank of Dubai PSC provides commercial and retail banking services in the United Arab Emirates.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price9.80 AED at the 13 Nov 2026 close
- Our value readFair vs our fair value, as of 13 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 8.01 AED to 11.96 AED, base estimate 9.19 AED (screen dated 2026-11-13).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Commercial Bank of Dubai PSC holds its Accumulation at $9.80. The statistical read favours the sellers, held for 79 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 79 days |
| Price at the screen | $9.80 |
| Valuation | 8.60 trailing · 10.65 forward price to earnings |
| Values screen | FAIL |
| Beta | 0.07 |
Five Screens, Shown in Full
Does not pass. Business activity: conventional financial services (interest-based)
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Its core business involves an activity the values screen does not clear. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Commercial Bank of Dubai PSC does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CBD.AE's ethical verdict changes
Today CBD.AE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades above our 9.19 AED fair value estimate, strong competitive moat, 1.90% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in AED, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 6.6% above the base estimate.
Third-party analyst targets: 2 covering, consensus Buy. The average target sits −0% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
ProjectionsWhere our models see it going: fair-value estimate 9.19 AED, with a range of 8.01 AED to 11.96 AED, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a strong moat and 65% profit margins. At the screened price it sits 7% above our 9.19 AED fair value: priced for the quality, not a bargain.
| Forward P/E | 10.7xexpensive even after accounting for its growth |
| Trailing P/E | 8.6xvery cheap relative to earnings |
| EPS, trailing | 1.14 |
| EPS, forward | 0.92 |
| Revenue growth | +1.9%slow but positive growth |
| Profit margin | 64.6%highly profitable on every dollar of sales |
| Return on equity | 20.3%an exceptional return on shareholder capital |
| Dividend yield | 6.43% |
| Beta | 0.07barely tracks the market's swings |
| 52-week range | 8.45 - 10.20 |
| Moat | STRONG |
| Market cap | $29.3B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to United Arab Emirates and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCBD.AE trades on DFM (the company is based in United Arab Emirates). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.3% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it none, with a mean price target of $10.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Al Morjan secures $2.5bn in financing for Rabigh 2 IPP expansion Yahoo Finance · 5 Oct 2026
- COMMERCIAL BANK OF DUBAI (CBD) RECOGNISED FOR EXCELLENCE IN DIGITAL BANKING TRANSFORMATION AT THE GLOBAL BRAND AWARDS 2026 Yahoo Finance · 17 Aug 2026
- Middle Eastern Dividend Stocks Featuring Commercial Bank of Dubai PSC And 2 More Simply Wall St. · 30 Mar 2026
- Middle Eastern Dividend Stocks Featuring Commercial Bank of Dubai PSC And 2 More Yahoo Finance · 30 Mar 2026
- 3 Middle Eastern Dividend Stocks To Consider With Up To 8.2% Yield Simply Wall St. · 4 Feb 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.15 | +1.9% | · | $1,019 | +1.9% |
| 2 months | $9.20 | +1.3% | · | $1,013 | +1.3% |
| 3 months | $9.60 | -2.9% | · | $971 | -2.9% |
| 6 months | $8.93 | +4.3% | $0.59 | $1,109 | +10.9% |
| 1 year | $8.12 | +14.7% | $0.59 | $1,219 | +21.9% |
| 2 years | $5.64 | +65.4% | $1.09 | $1,848 | +84.8% |
| 3 years | $3.71 | +150.9% | $1.54 | $2,923 | +192.3% |
| 5 years | $2.82 | +230.8% | $2.04 | $4,032 | +303.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CBD.AE does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.